On this page
Poteligeo
mogamulizumab-kpkc
351(a) Standalone BLA
Overview
Source: Purple BookProprietary name
Poteligeo
Proper name
mogamulizumab-kpkc
Licence type
351(a)
BLA number
761051
Applicant
Kyowa Kirin, Inc.
Center
CDER
Presentations
1
First licensure
—
Presentations
Source: Purple Book| Strength | Dosage form | Route | Presentation | Status | Licensed |
|---|---|---|---|---|---|
| 20MG/5ML (4MG/ML) | Injection | Intravenous | Single-Dose Vial | Rx | August 8, 2018 |
Exclusivity
Source: Purple Book| Kind | Expires |
|---|---|
| Orphan exclusivity | August 8, 2025 |
Sources for this page
| Purple Book | FDA | Licence type, presentations, reference product, exclusivity |